Access brought to you by: LOCKSS

Interventional Techniques & Devices

Results from the PARTNER Trial (Cohort A): Transfemoral TAVI Economically Attractive but Transapical TAVI More Costly
PARTNER Cohort B: TAVI Superior to Standard Therapy at Two Years
Transapical TAVI Inferior to SAVR in Operable Elderly Patients
Bioabsorbable Polymer Stent Noninferior to Permanent Polymer Stent
ISAR-REACT 4 – Bivalirudin Similar to Abciximab/Heparin in Reducing Ischemic Outcomes in NSTEMI and Has Significantly Less Bleeding
Valvular Heart Disease — From Clinic to Catheter Strategies
Transcatheter Valve: New Technologies and Techniques
The PARTNER Trial: A New Paradigm for Treating Valvular Heart Disease
EXAMINATION: Similar Outcomes with New-Generation DES Compared with BMS for Patients with Acute STEMI Undergoing PCI
IABP Do Not Reduce Infarct Size in Patients with STEMI without Cardiac Shock: The CRISP AMI Trial

Pages